Spain's Oryzon Moves To Madrid From Barcelona As Catalan Crisis Deepens
As tensions continue to rise in Catalonia in the aftermath of the illegal independence referendum, one of Spain's most high-profile biotechs has decided to move its headquarters to Madrid, leaving observers to wonder if other companies, including multinationals, will follow.
You may also be interested in...
After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.
The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
Five countries appear to be ahead in the battle to host the European Medicines Agency after Brexit, judging by the results of a European Commission assessment and an EMA staff survey, although much horse-trading among member states is expected before the winner is announced in November.